#1 Clinical Trials Search in Europe

Phospholipid Fraction, Porcine Lung

This article discusses a clinical trial investigating the use of a drug called “Phospholipid Fraction, Porcine Lung” (brand name Curosurf) in premature infants with Respiratory Distress Syndrome (RDS). The study aims to compare two different administration methods of this exogenous pulmonary surfactant to determine which approach is more effective in reducing the need for intubation during the first 72 hours of life.

Table of Contents

What is Phospholipid Fraction, Porcine Lung?

Phospholipid Fraction, Porcine Lung is a medication derived from pig lungs. It’s also known as Phospholipid Fraction from Pig Lung[1]. This medication is classified as a natural phospholipid, which means it contains substances naturally found in lung tissue[1]. The specific product used in the clinical trial is called Curosurf, which comes as a suspension for endotracheopulmonary instillation (a liquid that is carefully introduced into the lungs)[1].

Medical Condition: Respiratory Distress Syndrome in Premature Infants

This medication is used to treat Respiratory Distress Syndrome (RDS) in premature infants[1]. RDS is a serious breathing problem that affects some babies born too early. These babies’ lungs are not fully developed and lack a substance called surfactant, which helps keep the tiny air sacs in the lungs open. Without enough surfactant, breathing becomes difficult for these premature infants.

How Does the Medication Work?

Phospholipid Fraction, Porcine Lung acts as an exogenous surfactant. This means it’s a surfactant that comes from outside the body. When given to premature infants with RDS, it helps to replace the missing natural surfactant in their lungs. This can make breathing easier for these babies and potentially reduce the need for more invasive breathing support[1].

How is the Medication Administered?

The medication is given through endotracheopulmonary instillation[1]. This means it’s carefully introduced directly into the baby’s lungs through a thin tube placed in the windpipe. This method ensures that the medication reaches exactly where it’s needed – the tiny air sacs in the lungs.

Current Clinical Trial

A clinical trial is currently being conducted to study this medication further[1]. The main goal of this trial is to compare two different ways of giving the surfactant to premature babies with RDS:

  1. One method uses lung ultrasound to decide when to give the medication.
  2. The other method follows current guideline recommendations.

The researchers want to see if one method is better at reducing the number of times babies need to be intubated (have a breathing tube inserted) in the first 72 hours of life[1].

Eligibility for the Clinical Trial

The clinical trial has specific criteria for which babies can participate:

Inclusion Criteria:

  • Premature newborns of both sexes
  • Between 24 and 32 weeks of gestation and/or weighing 1500 grams or less at birth[1]

Exclusion Criteria:

Babies cannot participate if they have any of the following:

  • Chromosomal abnormalities or complex congenital malformations (birth defects)
  • Congenital lung diseases (lung problems present from birth)
  • Severe sepsis or septic shock (serious infections affecting the whole body)
  • Meconium aspiration syndrome (a breathing problem caused by inhaling first bowel movement)
  • If they’ve already received surfactant in the delivery room[1]

Parents must also give informed consent for their baby to participate in the trial[1].

Dosage Information

The maximum daily dose of the medication is 300 mg/kg (milligrams per kilogram of body weight)[1]. This means the amount given depends on how much the baby weighs. The maximum treatment period is one day[1]. However, it’s important to note that the exact dosage and treatment duration for each baby would be determined by their doctor based on their individual needs and response to the medication.

Aspect Details
Study Type Single-blind randomized clinical trial
Target Population Premature infants with Respiratory Distress Syndrome (RDS)
Drug Phospholipid Fraction, Porcine Lung (Curosurf)
Administration Method Endotracheopulmonary instillation
Primary Objective Compare efficacy of two administration schemes in reducing intubations
Primary Endpoint Intubation rate in the first 72 hours of life
Inclusion Criteria Premature newborns 24-32 weeks and/or ≤1500 grams at birth
Key Exclusion Criteria Chromosomal abnormalities, complex congenital malformations, severe sepsis

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this trial is to compare two administration schemes of exogenous pulmonary surfactant (Phospholipid Fraction, Porcine Lung) in preterm newborns with Respiratory Distress Syndrome. It aims to determine which method is more effective in reducing the number of intubations needed in the first 72 hours of life.
  • Who is eligible to participate in this study? The study includes premature newborns of both sexes, born between 24 and 32 weeks of gestation and/or weighing 1500 grams or less at birth. However, there are specific exclusion criteria, such as chromosomal abnormalities, complex congenital malformations, or severe sepsis.
  • What is the drug being used in this trial? The drug being used is called Phospholipid Fraction, Porcine Lung, with the brand name Curosurf. It is a natural phospholipid suspension used for endotracheopulmonary instillation in premature infants with Respiratory Distress Syndrome.
  • How is the drug administered to the patients? The drug is administered through endotracheopulmonary instillation, which means it is delivered directly into the trachea and bronchi of the lungs. The trial compares two different administration schemes, one based on lung ultrasound criteria and the other following current guideline recommendations.
  • What is the primary outcome being measured in this trial? The primary outcome being measured is the intubation rate in the first 72 hours of life. The study aims to determine which administration method of the surfactant is more effective in reducing the need for intubation in premature infants with Respiratory Distress Syndrome.

Ongoing Clinical Trials on Phospholipid Fraction, Porcine Lung

  • Study on Phospholipid Fraction from Porcine Lung for Premature Infants with Respiratory Distress Syndrome (RDS)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Respiratory Distress Syndrome (RDS): A breathing disorder that affects newborns, especially those born prematurely. It occurs when the lungs are not fully developed and lack a substance called surfactant, which helps the lungs expand and breathe properly.
  • Exogenous surfactant: A substance given to premature infants to replace the natural surfactant that their lungs may lack. It helps to reduce surface tension in the lungs, making breathing easier.
  • Intubation: A medical procedure where a tube is inserted through the mouth or nose into the trachea (windpipe) to help a patient breathe.
  • Endotracheopulmonary instillation: A method of administering medication directly into the trachea and lungs, often used for delivering surfactant to premature infants with RDS.
  • Phospholipid Fraction, Porcine Lung: A natural surfactant derived from pig lungs, used as a medication to treat Respiratory Distress Syndrome in premature infants.
  • Lung ultrasonography: A non-invasive imaging technique used to examine the lungs and diagnose various respiratory conditions, including RDS in premature infants.

References

  1. http://clinicaltrials.eu/trial/study-on-phospholipid-fraction-from-porcine-lung-for-premature-infants-with-respiratory-distress-syndrome-rds/